Lisata Therapeutics News

Positive Outlook for Lisata Therapeutics as Analyst Reaffirms Buy Rating Amid Strong Financials and Promising Clinical Trials

TipRanksMay 10 18:25

Earnings Call Summary | Lisata Therapeutics(LSTA.US) Q1 2024 Earnings Conference

The following is a summary of the Lisata Therapeutics, Inc. (LSTA) Q1 2024 Earnings Call Transcript:Financial Performance:Lisata reported Q1 2024 operating expenses of $6.6 million, a decrease of 3.6%

Futu NewsMay 10 11:13 · Conference Call

Lisata Therapeutics Net Loss Declines From a Year Earlier

Yahoo FinanceMay 10 05:47

Lisata Therapeutics (LSTA.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0, expected value of $0; earnings per share were -0.65 dollars, previous value was -0.77 dollars, and expected value was -0.72 dollars.

Lisata Therapeutics (LSTA.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0, expected value of $0; earnings per share were -0.65 dollars, previous value was -0.77 dollars, and expected value was -0.72 dollars.

Zhitong FinanceMay 10 05:20

Lisata Therapeutics | 10-Q: Quarterly report

Futu NewsMay 10 04:58 · Announcements

Press Release: Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024 Projected available cash

Dow JonesMay 10 04:05

Lisata Therapeutics Reports Strong 1Q Performance, Cash to Support Operations Into 2026 | NASDAQ:LSTA

Proactive InvestorsMay 10 00:48

Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events

BASKING RIDGE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies fo

Lisata TherapeuticsMay 8 12:00

Lisata Therapeutics Files for $150M Mixed Securities Shelf

Seeking AlphaMay 2 04:49

HC Wainwright & Co. : The Lisata Therapeutics (LSTA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $15.00.

HC Wainwright & Co. : The Lisata Therapeutics (LSTA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $15.00.

Zhitong FinanceApr 26 01:20

HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics with a Buy and maintains $15 price target.

Analyst UpgradesApr 26 01:17

Lisata Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 455.91% HC Wainwright & Co. → $15 Reiterates Buy → Buy 03/01/2024 455.91% HC Wainwright & Co. →

BenzingaApr 26 01:16

Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and SAGE Therapeutics (SAGE)

TipRanksApr 25 23:30

Lisata Therapeutics Advances Lead Asset LSTA1 for Treatment of Advanced Solid Tumors

Yahoo FinanceApr 23 22:48

Lisata Therapeutics And Qilu Pharmaceutical Announce First Patient Treated In Qilu's Phase 2 Trial Of LSTA1 In Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics And Qilu Pharmaceutical Announce First Patient Treated In Qilu's Phase 2 Trial Of LSTA1 In Patients With Metastatic Pancreatic Ductal Adenocarcinoma

BenzingaApr 23 19:32

Lisata Therapeutics Elevates James Nisco to Senior VP Finance

TipRanksApr 18 04:12

Lisata Therapeutics Receives U.S. FDA Orphan Drug Designation Granted To LSTA1 For Osteosarcoma

Lisata Therapeutics Receives U.S. FDA Orphan Drug Designation Granted To LSTA1 For Osteosarcoma

BenzingaApr 9 20:41

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Lisata Therapeutics, Inc. (Nasdaq: LSTA) today announced that the U.S. Food and Drug Administration (the "FDA") has granted Orphan Drug Designation ("ODD") to LSTA1, the Company's lead product candidate, for the treatment of osteosarcoma, a rare cancer that can develop in children, adolescents and young adults.

GlobeNewswireApr 9 20:30

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

BASKING RIDGE, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies

Lisata TherapeuticsApr 3 12:00

Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma

Yahoo FinanceMar 23 00:25